title: Evaluating an ER Degrader for Breast Cancer.
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D002934:Cinnamates / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005260:Female; D006801:Humans; D007191:Indazoles / Q000494:pharmacology / Q000627:therapeutic use*; D009154:Mutation; D011960:Receptors, Estrogen / Q000037:antagonists & inhibitors* / Q000235:genetics; D016896:Treatment Outcome
chemical_list: C000606997:3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; D000970:Antineoplastic Agents; D002934:Cinnamates; D007191:Indazoles; D011960:Receptors, Estrogen